The US Food and Drug Administration revealed that it has approved Baxter's genetically engineered protein, Rixubis, for treating patients suffering from a form of the chronic blood disorder hemophilia.
Figures released by the National Hemophilia Foundation reveals that hemophilia B is the second most common type of hemophilia and affects around 25,000 people across the globe.
The condition is caused when the patients fail to produce enough quantity of blood clotting factor needed for natural control of bleeding. Rixubis is the first new treatment approved in the last 15 years for treating hemophilia and is to be administered twice weekly.
"Rixubis is a welcome addition to our leading portfolio of hemophilia treatments, providing a much-needed treatment option for the thousands of people living with hemophilia B. This approval moves us one significant step forward in our pursuit of a bleed-free world, one patient at a time", the president of Baxter's BioScience business, Ludwig Hantson said.